Lv11
90 积分 2024-04-15 加入
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
3小时前
已完结
P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial
3小时前
已关闭
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
19天前
已完结
Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology
19天前
已关闭
Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations
19天前
已完结
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
19天前
已完结
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
19天前
已完结
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
20天前
已完结
[Consensus on the molecular residual disease testing in solid tumor]
1个月前
已完结
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
1个月前
已完结
皖公网安备34019202002308
